PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer

We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi; olaparib) and CDK4/6 inhibition (CDK4/6i; palbociclib or abemaciclib) combination therapy in castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) models. We demonstrated that combined ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Cheng, Peng, Shan, Pilié, Patrick G., Geng, Chuandong, Park, Sanghee, Manyam, Ganiraju C., Lu, Yungang, Yang, Guang, Tang, Zhe, Kondraganti, Shakuntala, Wang, Daoqi, Hudgens, Courtney W., Ledesma, Debora A., Marques-Piubelli, Mario L., Torres-Cabala, Carlos A., Curry, Jonathan L., Troncoso, Patricia, Corn, Paul G., Broom, Bradley M., Thompson, Timothy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456452/
https://www.ncbi.nlm.nih.gov/pubmed/34158347
http://dx.doi.org/10.1158/1535-7163.MCT-20-0848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456452/
https://www.ncbi.nlm.nih.gov/pubmed/34158347
http://dx.doi.org/10.1158/1535-7163.MCT-20-0848

Ejemplares similares